

BLISS GVS PHARMA LIMITED
 Regd Office.102, Hyde Park, Sakivihar Road,
 Andheri (East), Mumbai - 400 072
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER AND YEAR ENDED 30.06.2016

SR. NO.	PARTICULARS	STANDALONE			
		QUARTER ENDED			YEAR ENDED
		30.06.2016 (UNAUDITED)	31.03.2016 (UNAUDITED)	30.06.2015 (UNAUDITED)	31.03.2016 (AUDITED)
1	INCOME FROM OPERATIONS				
	(a) SALES (NET OF EXCISE DUTY)	6373.23	6092.27	7982.83	31969.24
	(b) OTHER OPERATING INCOME	215.85	468.00	42.05	669.11
	TOTAL INCOME FROM OPERATIONS(NET)	6589.08	6560.27	8024.88	32638.35
2	EXPENSES				
	a) COST OF MATERIALS CONSUMED	2998.84	3157.33	3517.88	13,647.00
	b) PURCHASE OF STOCK I N TRADE	-	-	36.37	36.37
	c) CHANGES IN INVENTORIES OF FINISHED GOODS ,WORK IN PROGRESS, STOCK IN TRADE	-160.88	124.02	15.90	-132.09
	d) EMPLOYEE BENEFITS EXPENSE	634.78	562.60	482.58	2188.89
	e) DEPRECIATION / AMORTISATION EXPENSES	144.30	143.92	135.22	585.24
	f) OTHER EXPENSES	1390.35	1150.83	1543.40	7288.36
	TOTAL EXPENSES	5007.38	5138.70	5731.34	23613.77
3	PROFIT FROM OPERATIONS BEFORE OTHER INCOME & FINANCE COSTS & EXCEPTIONAL ITEMS (1-2)	1581.70	1421.57	2293.55	9024.58
4	OTHER INCOME	741.85	267.34	630.78	2307.57
5	PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS (3+4)	2323.54	1688.91	2924.32	11332.15
6	FINANCE COSTS	290.08	305.13	291.18	1310.98
7	PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)	2033.46	1383.78	2633.14	10021.17
8	EXCEPTIONAL ITEMS	-	-	-	-
9	PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX (7 - 8)	2033.46	1383.78	2633.14	10021.17
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	650.71	915.71	1092.90	3459.70
11	NET PROFIT AFTER TAX FOR THE PERIOD (9 - 10)	1382.75	468.07	1540.25	6561.47
12	MINORITY INTEREST	-	-	-	-
13	NET PROFIT AFTER TAX & MINORITY INTEREST (11-12)	1382.75	468.07	1540.25	6561.47
14	PAID - UP EQUITY SHARE CAPITAL	1031.47	1031.47	1031.47	1031.47
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)				42175.96
16	BASIC AND DILUTED EPS (NOT ANNUALISED) OF FACE VALUE OF RS. 1/- EACH	1.34	0.45	1.49	6.36

NOTES:-

1.THE ABOVE UNAUDITED FINANCIAL RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON JULY 27, 2016

2.THE FIGURES FOR THE QUARTER ENDED MARCH 31, 2016 ARE THE BALANCING FIGURES BETWEEN THE AUDITED FIGURES IN RESPECT OF THE FULL FINANCIAL YEAR AND THE YEAR TO DATE PUBLISHED RESULTS FOR THE NINE MONTHS ENDED DECEMBER 31, 2015.

3.THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.
 GEOGRAPHICAL SEGMENT DISCLOSURE:-

- I) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED JUNE 30, 2016 - RS. 498.89 LACS AND RS. 5874.34 LACS RESPECTIVELY
 II) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED MARCH 31, 2016- RS. 375.84 LACS AND RS. 5716.43 LACS RESPECTIVELY
 III) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED JUNE 30, 2015- RS. 674.43 LACS AND RS. 7308.40 LACS RESPECTIVELY
 IV) REVENUES WITHIN AND OUTSIDE INDIA FOR THE YEAR ENDED MARCH 31, 2016- RS. 2045.73 LACS AND RS. 29923.51 LACS RESPECTIVELY

4. FIGURES FOR THE PREVIOUS PERIODS HAVE BEEN REGROUPED/REARRANGED WHEREVER NECESSARY.

PLACE : MUMBAI
 DATE : 27th July 2016

FOR BLISS GVS PHARMA LTD
 SD/-
 S.N. KAMATH
 MANAGING DIRECTOR

BLISS GVS PHARMA LIMITED
 Regd Office, 102, Hyde Park, Sakivihar Road,
 Andheri (East), Mumbai - 400 072
STATEMENT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30.06.2016

(Rs. In Lacs)

PART - I

SR. NO.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30.06.2016 (UNAUDITED)	31.03.2016 (UNAUDITED)	30.06.2015 (UNAUDITED)	31.03.2016 (AUDITED)
1	INCOME FROM OPERATIONS				
	(a) SALES (NET OF EXCISE DUTY)	13770.93	14041.07	9347.73	53671.30
	(b) OTHER OPERATING INCOME	243.41	771.53	140.43	1018.11
	TOTAL INCOME FROM OPERATIONS(NET)	14014.34	14812.60	9488.16	54689.41
2	EXPENSES				
	a) COST OF MATERIAL CONSUMED	6586.63	7457.36	3150.67	25,589.07
	b) PURCHASE OF STOCK IN TRADE	90.96	897.00	131.28	508.76
	c) CHANGES IN INVENTORIES OF FINISHED GOODS ,WORK IN PROGRESS, STOCK IN TRADE	(105.41)	(157.54)	68.18	(421.30)
	d) EMPLOYEE BENEFITS EXPENSE	1081.01	886.79	754.73	3373.65
	e) DEPRECIATION / AMORTISATION EXPENSES	360.27	345.81	304.17	1326.00
	f) OTHER EXPENSES	2424.50	2360.48	1889.50	10108.90
	TOTAL EXPENSES	10437.96	11789.90	6298.53	40485.08
3	PROFIT FROM OPERATIONS BEFORE OTHER INCOME & FINANCE COSTS & EXCEPTIONAL ITEMS (1-2)	3576.38	3022.70	3189.63	14204.33
4	OTHER INCOME	871.64	394.09	647.41	2435.00
5	PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS (3+4)	4448.02	3416.79	3837.04	16639.33
6	FINANCE COSTS	405.20	612.59	510.32	1819.86
7	PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)	4042.82	2804.20	3326.72	14819.47
8	EXCEPTIONAL ITEMS				
9	PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX (7 - 8)	4042.82	2804.20	3326.72	14819.47
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	1298.66	1472.92	1329.91	4804.91
11	NET PROFIT AFTER TAX FOR THE PERIOD (9 - 10)	2744.16	1331.28	1996.81	10014.56
12	MINORITY INTEREST	678.67	527.37	42.55	1766.30
13	NET PROFIT AFTER TAX & MINORITY INTEREST (11-12)	2065.49	803.91	1954.26	8248.26
14	PAID - UP EQUITY SHARE CAPITAL	1031.47	1031.47	1031.47	1031.47
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)				40230.77
16	BASIC AND DILUTED EPS (NOT ANNUALISED) PER SHARE OF FACE VALUE OF Re. 1/- EACH	2.00	0.78	1.89	8.00

NOTES:-

1. THE ABOVE UNAUDITED FINANCIAL RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD OF DIRECTORS AT ITS MEETING HELD ON JULY 27, 2016

2. THE FIGURES FOR THE QUARTER ENDED MARCH 31, 2016 ARE THE BALANCING FIGURES BETWEEN THE AUDITED FIGURES IN RESPECT OF THE FULL FINANCIAL YEAR ENDED March 31, 2016 AND THE YEAR TO DATE THOSE FOR THE NINE MONTHS ENDED DECEMBER 31, 2015.

3. THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.

GEOGRAPHICAL SEGMENT DISCLOSURE:-

- I) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED JUNE 30, 2016 - RS. 1,291.75 LACS AND RS. 12,479.18 LACS RESPECTIVELY.
- II) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED MARCH 31, 2016- RS. 1,064.37 LACS AND RS. 12,976.70 LACS RESPECTIVELY.
- III) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED JUNE 31, 2015- RS. 1,063.83 LACS AND RS. 8,283.90 LACS RESPECTIVELY.
- IV) REVENUES WITHIN AND OUTSIDE INDIA FOR THE YEAR ENDED MARCH 31, 2016- RS. 5,413.38 LACS AND RS. 48257.92 LACS RESPECTIVELY.

4. FIGURES FOR THE PREVIOUS PERIODS HAVE BEEN REGROUPED/REARRANGED WHEREVER NECESSARY.

PLACE : MUMBAI
 DATE : 27th July 2016

FOR BLISS GVS PHARMA LTD
 SD/-
 S.N. KAMATH
 MANAGING DIRECTOR